Table Info

Table 1.

Demographic, clinic, and histologic characteristics of the patients, demographic characteristics of the controls, the cytokines’ concentrations in the systemic circulation, and comparisons of the three groups

Individuals/Diagnostic	Age(year)/Gender	Type/Site of the tumor	IL-2 (pg/mL)	IL-4 (pg/mL)	IL-10 (pg/mL)	TNF-α (pg/mL)
P1 (XP)	31/F	BCC (nose)	0.78	244	0	47.17
P2 (XP)	35/F	BCC + SCC (cheek)	4.35	0	0	0
P3 (XP)	17/M	Multiple carcinomas (BCC + SCC) + melanoma (ear)	2.38	0	0.01	27.83
P4 (XP)	11/F	Multiple carcinomas (BCC + SCC) face	0.08	0	8.33	47
P5 (XP)	39/F	BCC (nasogenian furrow)	0	0	0	30.33
P6 (non-XP)	42/M	BCC (cheek)	4.77	4.48	0	0
P7 (non-XP)	59/F	SCC in situ (left side)	0.76	0	23.50	0
P8 (non-XP)	74/M	SCC (nasogenian furrow)	1.37	0	0.60	0
P9 (non-XP)	64/M	SCC (nose slot + right eye + chest)	0.47	4.33	0	0
P10 (non-XP)	55/M	BCC (cheek)	1.67	0	0	0
P11 (non-XP)	67/F	Multiple carcinomas BCC + SCC (face, cheek, and eyelids)	3.51	0	7.17	0
C1 (Control)	57/F	-	0.77	0	0	0
C2 (Control)	39/F	-	0	0	0.03	0
C3 (Control)	45/F	-	1.43	4.17	0	0
Median concentrations of the cytokines	XP		0.78	0.00	0.00	30.33
	Non-XP		1.52	0.00	0.30	0.00
	Control		0.77	0.00	0.00	0.00
Comparisons of the median plasma concentrations of the cytokines in the three subgroups	XP vs non-XP (P value)		0.465	0.816	0.619	0.011
	XP vs Controls (P value)		> 0.999	0.845	0.864	0.050
	Non-XP vs Controls (P value)		0.796	0.795	0.396	> 0.999

Declarations

Acknowledgments

This work was supported by the Immunology, Dermatology and Oncology Department at INSERM Research Center 841, Henri Mondor Hospital, Créteil, France. We are grateful to Professor Armand Bensussan, Director of the Department, for having hosted us in his laboratory. We also wish to thank Professor Dragan Jovanovic of Mac Gill University, Canada, for helpful discussions. We also would like to thank Professor Scott King Johnson for language editing.

Author contributions

KA: Conceptualization, Data curation, Investigation, Methodology, Project administration, Validation, Writing—original draft. JB: Conceptualization, Formal analysis, Methodology, Validation, Writing—review & editing. FEM: Conceptualization, Investigation, Methodology, Validation, Writing—review & editing. HB: Conceptualization, Investigation, Methodology, Resources, Validation, Writing—review & editing. All the co-authors gave their final approval of the version to be published.

Conflicts of interest

The authors have no conflicts of interest to declare.

Ethical approval

Our study was approved by the Ethics Committee of A. Mami Hospital, Lariana, Tunisia. The study is in accordance with the Helsinki Declaration.

Consent to participate

Informed consent to participate in the study was obtained from all the participants.

Consent to publication

Not applicable.

Availability of data and materials

All supporting data are available from the corresponding author upon request.

Funding

Not applicable.

Copyright

References

de Gruijl FR, van der Leun JC. Estimate of the wavelength dependency of ultraviolet carcinogenesis in humans and its relevance to the risk assessment of a stratospheric ozone depletion. Health Phys. 1994;67:319–25. [DOI] [PubMed]

Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci. 2000;23:1–11. [DOI] [PubMed]

Boonstra A, van Oudenaren A, Barendregt B, An L, Leenen PJ, Savelkoul HF. UVB irradiation modulates systemic immune responses by affecting cytokine production of antigen-presenting cells. Int Immunol. 2000;12:1531–8. [DOI] [PubMed]

Weinstock MA. Death from skin cancer among the elderly: epidemiological patterns. Arch Dermatol. 1997;133:1207–9. [DOI] [PubMed]

Gremmel T, Wild S, Schuller W, Kürten V, Dietz K, Krutmann J, et al. Six Genes Associated with the Clinical Phenotypes of Individuals with Deficient and Proficient DNA Repair. Translational oncogenomics. 2008;3:1–13. [DOI] [PubMed] [PMC]

Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem. 1997;272:23465–8. [DOI] [PubMed]

Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis. 2011;6:70. [DOI] [PubMed] [PMC]

Gaspari AA, Fleisher TA, Kraemer KH. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest. 1993;92:1135–42. [DOI] [PubMed] [PMC]

Miyauchi-Hashimoto H, Okamoto H, Tanaka K, Horio T. Ultraviolet radiation-induced suppression of natural killer cell activity is enhanced in xeroderma pigmentosum group A (XPA) model mice. J Invest Dermatol. 1999;112:965–70. [DOI] [PubMed]

10.

Jimbo T, Ichihashi M, Mishima Y, Fujiwara Y. Role of excision repair in UVB-induced depletion and recovery of human epidermal Langerhans cells. Arch Dermatol. 1992;128:61–7. [DOI] [PubMed]

11.

Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol. 2012;22:299–309. [DOI] [PubMed]

12.

van Engelen BG, Hiel JA, Gabreëls FJ, van den Heuvel LP, van Gent DC, Weemaes CM. Decreased immunoglobulin class switching in Nijmegen Breakage syndrome due to the DNA repair defect. Hum Immunol. 2001;62:1324–7. [DOI] [PubMed]

13.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. [DOI] [PubMed] [PMC]

14.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. [DOI] [PubMed] [PMC]

15.

Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29:1275–88. [DOI] [PubMed] [PMC]

16.

Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–56. [DOI] [PubMed]

17.

Ong ZY, Gibson RJ, Bowen JM, Stringer AM, Darby JM, Logan RM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol. 2010;5:22. [DOI] [PubMed] [PMC]

18.

Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, et al. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 2007;67:11811–20. [DOI] [PubMed]

19.

Hoffmann TK, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2007;29:472–8. [DOI] [PubMed]

20.

Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CA. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:5–11. [DOI] [PubMed]

21.

Teresa Pinto A, Laranjeiro Pinto M, Patrícia Cardoso A, Monteiro C, Teixeira Pinto M, Filipe Maia A, et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Sci Rep. 2016;6:18765. [DOI] [PubMed] [PMC]

22.

Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:58. [DOI] [PubMed] [PMC]

23.

Sabitha M, Sanoj Rejinold N, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Development and evaluation of 5-fluorouracil loaded chitin nanogels for treatment of skin cancer. Carbohydr Polym. 2013;91:48–57. [DOI] [PubMed]

24.

Kirkup ME, Narayan S, Kennedy CT. Cutaneous recall reactions with systemic fluorouracil. Dermatology. 2003;206:175–6. [DOI] [PubMed]

25.

Wang L, Saito K, Toda M, Hori T, Torii M, Ma N, et al. UV irradiation after immunization induces type 1 regulatory T cells that suppress Th2-type immune responses via secretion of IL-10. Immunobiology. 2010;215:124–32. [DOI] [PubMed]

26.

Satoh-Takayama N. Heterogeneity and diversity of group 3 innate lymphoid cells: new cells on the block. Int Immunol. 2016;28:29–34. [DOI] [PubMed]

27.

Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A. 2006;103:2274–9. [DOI] [PubMed] [PMC]

28.

Green VL, Michno A, Greenman J, Stafford ND. Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients. Results Immunol. 2011;2:1–6. [DOI] [PubMed] [PMC]

29.

Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153–65. [DOI] [PubMed] [PMC]

30.

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–97. [DOI] [PubMed] [PMC]

31.

Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother. 2004;53:79–85. [DOI] [PubMed] [PMC]

32.

Günaydın RÖ, Kesikli SA, Kansu E, Hoşal AŞ. Identification of the peripheral blood levels of interleukin‐12, interleukin‐10, and transforming growth factor‐β in patients with laryngeal squamous cell carcinoma. Head neck. 2012;34:393–7. [DOI] [PubMed]

33.

Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol. 2007;121:246–52. [DOI] [PubMed]

34.

Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621–67. [DOI] [PubMed]

35.

Lee S, Cha J, Kim I, Yoon JC, Lee HJ, Park SW, et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun. 2014;445:584–90. [DOI] [PubMed]

36.

Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA, et al. Abnormal T regulatory cells (Tregs: FOXP3⁺, CTLA-4⁺), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013;11:16. [DOI] [PubMed] [PMC]

37.

Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990;82:57–62. [DOI] [PubMed] [PMC]

38.

Wongkulab P, Wipasa J, Chaiwarith R, Supparatpinyo K. Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand. PLoS One. 2013;8:e76371. [DOI] [PubMed] [PMC]

39.

Bratke K, Goettsching H, Kuepper M, Geyer S, Luttmann W, Virchow JC. Interleukin-4 suppresses the cytotoxic potential of in vitro generated, adaptive regulatory CD4⁺T cells by down-regulation of granzyme B. Immunology. 2009;127:338–44. [DOI] [PubMed] [PMC]

40.

Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100:1215–9. [DOI] [PubMed]

41.

Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers. 2004;19:130–4. [DOI] [PubMed]

42.

Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol. 2005;174:1801–10. [DOI] [PubMed]

43.

Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol. 2013;23:273–80. [DOI] [PubMed]

44.

Cardin R, Piciocchi M, Bortolami M, Kotsafti A, Barzon L, Lavezzo E, et al. Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway. World J Gastroenterol. 2014;20:3078–86. [DOI] [PubMed] [PMC]

45.

Poljšak B, Dahmane R. Free radicals and extrinsic skin aging. Dermatol Res Pract. 2012;2012:135206. [DOI] [PubMed] [PMC]

46.

Geng Y, Chandrasekaran S, Hsu J, Gidwani M, Hughes AD, King MR. Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One. 2013;8:e54959. [DOI] [PubMed] [PMC]

47.

Wang X, Montoyo-Pujol YG, Bermudez S, Corpas G, Martin A, Almazan F, et al. Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis. J Oncol. 2021;2021:6610769. [DOI] [PubMed] [PMC]

48.

Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16:1173–9. [DOI] [PubMed]